GlassScriptPhysician profile
Skylar Mccormick
NPI 1780355016
$1,700.87
in general payments reported to CMS, 2019-2025
17 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $331 · 2024: $639 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.46 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $211.25 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $101.95 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Vanda Pharmaceuticals INC. | $101.36 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $93.06 | 2024-2025 | Qelbree |
| Alkermes, INC. | $75.46 | 2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $68.77 | 2023-2025 | Auvelity, Sunosi |
| Dexcom, INC. | $60.50 | 2024-2025 | Dexcom G6 Transmitter |
| Corium, LLC | $46.68 | 2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $39.80 | 2023-2025 | Invega Sustenna, Spravato |
| Novartis Pharmaceuticals Corporation | $37.35 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.32 | 2023 | |
| Phathom Pharmaceuticals, INC. | $25.25 | 2024-2025 | Voquezna |
| Lundbeck LLC | $16.78 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $16.61 | 2023 | Quviviq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.48 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $14.79 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skylar Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.